BioSpace News Archive

Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, has entered into a broad research agreement with Memorial Sloan Kettering Cancer Center.

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the H.C. Wainwright Global Investment Conference 2022.

Lassen Therapeutics , a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, is presenting new preclinical data on LASN01.

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced that members of IMV’s executive management team will be participating in person at the H.C. Wainwright Global Investment Conference, which will be held in person and virtually May 23-26, 2022,

Metagenomi Presents New Preclinical Data at ASGCT on Proprietary, Highly Efficient CRISPR Gene Editing Systems and a Novel Family of CRISPR-Associated Transposases (CASTs).

Cynosure, LLC, a leader in medical aesthetics systems and technologies, announced today a new investment of $60 million from lead investor Clayton, Dubilier & Rice.

Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess, today announced that it will present new clinical pharmacology data at the 24th European Congress of Endocrinology (ECE 2022) on its lead candidate, SPI-62, an HSD-1 inhibitor.

Histogen Inc. announced that Steven J. Mento, Ph.D., Histogen’s Executive Chairman and Interim President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference.

Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies, will participate in the following upcoming investor conferences.

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), today announced results from a preclinical study of RKER-012 on pulmonary arterial pressure and right ventricle hypertrophy in an established rodent model of pulmonary arterial hypertension (“PAH”) at the American Thoracic Society (“ATS”) International Conference held May 13 through 18, 2022.